National Healthcare Quality and Disparities Report
Latest available findings on quality of and access to health care
Data
- Data Infographics
- Data Visualizations
- Data Tools
- Data Innovations
- All-Payer Claims Database
- Healthcare Cost and Utilization Project (HCUP)
- Medical Expenditure Panel Survey (MEPS)
- AHRQ Quality Indicator Tools for Data Analytics
- State Snapshots
- United States Health Information Knowledgebase (USHIK)
- Data Sources Available from AHRQ
Search All Research Studies
AHRQ Research Studies
Sign up: AHRQ Research Studies Email updates
Research Studies is a compilation of published research articles funded by AHRQ or authored by AHRQ researchers.
Results
1 to 3 of 3 Research Studies DisplayedShmuel S, Leonard CE, Bykov K
Breaking research silos and stimulating "innovation at the edges" in epidemiology.
The authors discuss the importance of promoting an exchange of ideas across seemingly disparate epidemiologic subdisciplines. This exchange could lead to opportunities to learn from and to merge knowledge across subdisciplines, as well as promote "innovation at the edges." The authors also outline specific steps to promote such innovation at the researcher, institution, and professional society level.
AHRQ-funded; HS027623.
Citation: Shmuel S, Leonard CE, Bykov K .
Breaking research silos and stimulating "innovation at the edges" in epidemiology.
Am J Epidemiol 2023 Feb 24;192(3):323-27. doi: 10.1093/aje/kwac192.
Keywords: Evidence-Based Practice, Research Methodologies, Medication
Wang L, Rouse B, Marks-Anglin A
Rapid network meta-analysis using data from Food and Drug Administration approval packages is feasible but with limitations.
The purpose of this study was to test rapid approaches that use Drugs@FDA (a public database of approved drugs) and ClinicalTrials.gov to identify trials and to compare these two sources with bibliographic databases as an evidence base for a systematic review and network meta-analysis (NMA). The investigators concluded that a rapid NMA approach using data from Drugs@FDA was feasible but had its own limitations. They asserted that reporting of trial design and results can be improved in both the drug approval packages and on ClinicalTrials.gov.
AHRQ-funded; HS024788.
Citation: Wang L, Rouse B, Marks-Anglin A .
Rapid network meta-analysis using data from Food and Drug Administration approval packages is feasible but with limitations.
J Clin Epidemiol 2019 Oct;114:84-94. doi: 10.1016/j.jclinepi.2019.06.010..
Keywords: Medication, Research Methodologies, Evidence-Based Practice
Camp KM, Parisi MA, Acosta PB
AHRQ Author: Chang CS
Phenylketonuria Scientific Review Conference: state of the science and future research needs.
An NIH State-of-the-Science Conference was convened in 2012 to address new findings, particularly the use of the medication sapropterin to treat some individuals with phenylketonuria (PKU), and to develop a research agenda. An AHRQ Evidence-based Practice Center conducted a systematic review of adjuvant treatments for PKU and presented its conclusions at the conference. New drugs that are safe, efficacious, and impact a larger proportion of individuals with PKU are needed. The identification of a research agenda has facilitated the development of clinical practice guidelines by professional organizations and serves as a model for other inborn errors of metabolism.
AHRQ-authored.
Citation: Camp KM, Parisi MA, Acosta PB .
Phenylketonuria Scientific Review Conference: state of the science and future research needs.
Mol Genet Metab 2014 Jun;112(2):87-122. doi: 10.1016/j.ymgme.2014.02.013.
.
.
Keywords: Comparative Effectiveness, Evidence-Based Practice, Guidelines, Medication, Research Methodologies